The innovation of this paper is to prepare HA-Gd2O3-NPs and combine them with EGFR-TKI in the clinical treatment of NSCLC, in order to explore the clinical efficacy and safety of their combined effect and provide reference basis for clinical treatment. Here, EGFR is linked to non-small cell lung carcinoma.